

Special Issue

Gastrointestinal Stromal Tumors (GIST): Opportunity and Challenges in Diagnosis and Treatment

Message from the Guest Editors

Gastrointestinal stromal tumors are a subgroup of mesenchymal tumors originating from the interstitial cells of Cajal, which can arise from any part of the gastrointestinal tract, most frequently from the stomach and small intestine, characterized by the expression of the cell-surface transmembrane receptor KIT with tyrosine kinase activity in approximately 95% of tumors. Tumor mutational status is biologically and clinically important in GISTs and makes this tumor a paradigmatic model of oncogene addiction. Constitutively activating mutations in the gene coding for KIT proto-oncogene receptor tyrosine kinase (KIT) or in platelet-derived growth factor receptor alpha (PDGFRA) oncogenes are alternative and mutually exclusive, highlighting their important role in the pathogenesis of GISTs. KIT and PDGFRA mutations represent known prognostic and predictive biomarkers for GISTs and are useful in driving the choice of therapy in the adjuvant and metastatic setting. We are pleased to invite experts in this field to review the current approaches to managing patients with GIST and focus on the molecular and immunological aspects of this heterogeneous group of neoplasms.

Guest Editors

Prof. Dr. Antonio Russo
Prof. Dr. Giuseppe Badalamenti
Dr. Lorena Incorvaia

Deadline for manuscript submissions

closed (1 June 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/101913

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)